Tata India Pharma & Healthcare Fund-Regular Plan-Growth
Category: Equity: Sectoral-Pharma and Healthcare
Launch Date: 28-12-2015
AUM:
₹ 1,282 Cr
Expense Ratio
2.1%
Benchmark
NIFTY Pharma TRI
ISIN
INF277K016A9
Minimum Investment
5000.0
Minimum Topup
1000.0
Minimum SIP Amount
100
Fund Manager
Meeta Shetty, Rajat Srivastava
| Fund Performance | 1Y (%) | 3Y (%) | 5Y (%) |
|---|---|---|---|
| Tata India Pharma & Healthcare Fund-Regular Plan-Growth | 5.19 | 23.57 | 18.85 |
| Nifty Pharma TRI | 1.37 | 20.75 | 14.59 |
If you invested in this fund:
In the past (time duration):
Total value today:
0
Returns:
0%
If you invested in this fund:
In the past (time duration):
Total value today:
0
Returns:
0%
Overview
NAV
31.0352
Last change
-0.1 (-0.3299%)
Fund Size (AUM)
₹ 1,282 Cr
Performance
12.44% (Inception)
Asset Allocation
Equity
Debt
Others
Nav Movement
Investment Objective
The scheme seeks long term capital appreciation by investing atleast 80% of it's net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.
Fund Manager
Meeta Shetty, Rajat Srivastava
Riskometer
Very High
Top 10 Holdings
| Company | Holdings (%) |
|---|---|
| SUN PHARMACEUTICAL INDUSTRIES LTD. EQ NEW F.V. RE.1/- | 10.92 |
| CIPLA LIMITED EQ NEW FV RS.2/- | 6.62 |
| APOLLO HOSPITALS ENTERPRISE LIMITED EQ NEW F.V. RS.5/- | 5.2 |
| LUPIN LIMITED EQ NEW F.V. RS.2/- | 4.77 |
| A) REPO | 4.56 |
| HEALTHCARE GLOBAL ENTERPRISES LTD EQ | 4.38 |
| TORRENT PHARMACEUTICALS LIMITED EQ NEW FV RS.5/- | 4.32 |
| ASTER DM HEALTHCARE LIMITED EQ | 4.32 |
| FORTIS HEALTHCARE LIMITED. EQ | 4.0 |
| ALKEM LABORATORIES LIMITED EQ | 4.0 |
Sector Allocation
| Sector | Holdings (%) |
|---|---|
| Healthcare | 90.38 |
| Financial Services | 2.6 |
| Consumer Services | 0.83 |